Pharmaxis’ CF Drug Bronchitol Gets Thumbs Down From FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee members said pediatric efficacy and safety concerns precluded approval of dry powder mannitol for the broad indication of improving pulmonary function in cystic fibrosis patients ages six years and older.
You may also be interested in...
Chiesi Takes CF Product To Advisory Cmte. With Modest Efficacy, Many Questions
Bronchitol is set to make its second appearance before a US FDA advisory committee, and Chiesi hopes to rely on the drug’s novel mechanism of action and the unmet need in cystic fibrosis to overcome the agency’s concerns about the underlying clinical data.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.
Preterm Birth Prevention Studies Need To Look Beyond Makena Endpoints, Experts Say
Gestational age and a binary, neonatal composite endpoint are insufficient to assess outcomes that are important to babies and families, clinicians and researchers say, suggesting development of continuous variables or scales with weighted components and a comparison of outcomes among newborns in gestational age ‘buckets.’